Shoichi Ozawa

Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels,GPCRs, and transporters

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.

Our founding discoveries came from the labs of Prof. Takagi and Prof Suga (the 2023 winner of the Wolf Prize in Chemistry), both of whom are deeply involved in our R&D to this day. Their innovations enable a novel class of biologics, called “Neobiologics,” that break existing boundaries in biological drug development and will ultimately better, more cost-effective treatments for patients. Internally and with our partners, we are advancing a robust portfolio of products: 1. cMet agonist to HGF (hepatocyte growth factor) to tackle NASH (non-alcoholic steatohepatitis)/fibrosis; currently in IND enabling studies. 2. TrkB agonist of BDNF (brain-derived neurotrophic factor) to tackle neurodegenerative diseases like Alzheimers Disease and Parkinson’s Disease; currently in vivo studies. 3. Immuno-oncology bi-specific with T-cell engaging activity and a tumor antigen-specific binder; currently in vitro R&D. 4. Undisclosed assets in various stages. This pipeline builds off our core RaPID System and LassoGraft Technology® (LGT) platforms. The RaPID System selects highly active cyclic peptides that tightly bind to drug-target proteins from our diverse library. These peptides are then genetically grafted onto scaffold proteins using LGT to create Neobiologics. Neobiologics break multiple current boundaries for biologics, such as access across the blood-brain barrier, 3D topological design control, multifunctionality (bi-specific, tri-specific, etc.), wide applicability from AAV capsid modulation to antibodies to therapeutic proteins and superior development speeds that drop development costs significantly. Selected publications 1. Mihara, E et al. Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins. Nature Communications (2021)2:1543 2. Sakai, K et al. Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions. Nature Biomedical Engineering 7, 164-176 (2023)

IgGenix is a clinical-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.

Alivexis, Inc. (formerly Modulus Discovery, Inc) is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, we are propelling forward our distinct portfolio of small molecule drugs along with a variety of research and development collaborations.

MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world. Today, its platform integrates AI with evolutionary molecular engineering, next-generation sequencing, laboratory automation technologies, and a proprietary database containing more than one billion molecular entries. These capabilities enable the delivery of diverse, high affinity, specific, and functional antibodies and peptides for researchers. MOLCURE is partnering with innovative companies to discover therapeutics with the potential to benefit patients around the world.

Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels,GPCRs, and transporters

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.

Our founding discoveries came from the labs of Prof. Takagi and Prof Suga (the 2023 winner of the Wolf Prize in Chemistry), both of whom are deeply involved in our R&D to this day. Their innovations enable a novel class of biologics, called “Neobiologics,” that break existing boundaries in biological drug development and will ultimately better, more cost-effective treatments for patients. Internally and with our partners, we are advancing a robust portfolio of products: 1. cMet agonist to HGF (hepatocyte growth factor) to tackle NASH (non-alcoholic steatohepatitis)/fibrosis; currently in IND enabling studies. 2. TrkB agonist of BDNF (brain-derived neurotrophic factor) to tackle neurodegenerative diseases like Alzheimers Disease and Parkinson’s Disease; currently in vivo studies. 3. Immuno-oncology bi-specific with T-cell engaging activity and a tumor antigen-specific binder; currently in vitro R&D. 4. Undisclosed assets in various stages. This pipeline builds off our core RaPID System and LassoGraft Technology® (LGT) platforms. The RaPID System selects highly active cyclic peptides that tightly bind to drug-target proteins from our diverse library. These peptides are then genetically grafted onto scaffold proteins using LGT to create Neobiologics. Neobiologics break multiple current boundaries for biologics, such as access across the blood-brain barrier, 3D topological design control, multifunctionality (bi-specific, tri-specific, etc.), wide applicability from AAV capsid modulation to antibodies to therapeutic proteins and superior development speeds that drop development costs significantly. Selected publications 1. Mihara, E et al. Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins. Nature Communications (2021)2:1543 2. Sakai, K et al. Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions. Nature Biomedical Engineering 7, 164-176 (2023)

IgGenix is a clinical-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.